Absolute glycan quantitation is more complex than simply integrating peak areas. It requires consideration that same mass does not mean same ionisation efficiency. Ratios are adequate for QC trending, pseudo-absolutist methods normalise to an internal standard isotopologue peak, and true absolute quantitation relies on the use of stoichiometric standards. Each level appropriately trades off analytical burden with clinical consequence.
The goal of quantitative glycan analysis is complicated by several factors that go beyond simply determining signal intensity levels. Glycans are structurally diverse and detection efficiency can vary due to differences in physiochemical properties. Additionally, quantitation errors can occur at each step of the analytical process. Ionization efficiency may vary across glycan structures, which challenges the assumption that the signal obtained by mass spectrometry or chromatography is proportional to either the absolute or relative amount of glycans present. Signal suppression from the matrix itself as well as biases from glycan release and derivatization methods can also occur.
Analytical workflow and sensitivity improvement.1,5
The structural heterogeneity of glycans also negatively impacts the homogeneity of response. Extent of sialylation, patterns of fucosylation and the branching of the glycan antennae significantly impact ionization efficiencies in mass spectrometry and chromatographic properties. Neutral glycans ionize differently than glycans with acidic residues. Isomers that have the same mass can often give different responses due to differences in structure. This requires the use of response factors or normalization within a class to eliminate quantitative errors when directly comparing signals from different molecules.
The concentrations determined during glycan analysis are influenced by several sources of variation during sample preparation, such as differences in protein yield, enzymatic digestion efficiency (glycan accessibility), derivatization efficiency (reaction kinetics), solid phase extraction (recovery dependent on glycan polarity) and chromatography (resolution differences between isomers). MS analysis also contains variation introduced by crystallization differences of the sample matrix. Without consistent internal standards that are added at the beginning and run through the entire process using isotopes distinct from the sample (such as an isotope-labeled glucose serum pool), it is difficult to determine the absolute abundance of a glycan species.
| Analytical Stage | Bias Mechanism | Impact Magnitude | Corrective Approach |
| Protein extraction | Differential glycoform solubility | Moderate | Detergent standardization; buffer optimization |
| Enzymatic release | Variable accessibility; steric hindrance | High | Optimized incubation conditions; multiple enzyme cocktails |
| Derivatization | Reaction efficiency heterogeneity | Moderate to high | Reaction time optimization; isotope-labeled process standards |
| Purification | Differential recovery by polarity | Moderate | Isotopically labeled internal standards added pre-purification |
| Chromatographic injection | Sample matrix effects | Variable | Matrix-matched calibration; dilution protocols |
| Mass spectrometric detection | Ionization suppression/enhancement | High | Internal standards structurally matched to analytes; response factors |
One common issue is the mistaken interpretation of relative abundance as being quantitative. For example, from a biological standpoint one might mistakenly interpret an increase or decrease in percent composition to be caused by regulation of that glycan when it could be caused by a change in total concentration of the glycoprotein. Another common assumption is that peak areas represent equal numbers of molecules for each glycan type when there can be significant ionization efficiency differences between nonsialylated and sialylated glycans. Interpreting semi-quantitative results as being quantitative can lead to false results being published that are not fit for clinical applications.
The three tiers of quantitative glycan analysis involve differing levels of sample processing/calibration as well as ease of biological interpretation. Methods span from basic composition analysis to strict molar quantification. Advantages and disadvantages exist between speed, expense and quantitative capabilities and should be considered when choosing which strategy best suits your needs.
Absolute quantitation is calculated by relative abundance values. Here glycan composition is reported as a percentage of the overall spectral contribution instead of quantitation as a molar amount. Each glycan intensity is normalized to the total summed peak area. This method corrects for differences in sample loading or run-to-run variation in sensitivity of the MS instrument. While cost-effective and relatively easy to implement, the disadvantage of this method is if there are biological differences in overall glycosylation between samples, it will give you a false comparison. Advantage: it is useful when comparing differences in glycan composition between diseased and normal samples as opposed to differences in concentration.
Absolute quantitation determines the actual molar concentrations of glycans in a sample by spiking the sample with isotopically labeled internal standards. The internal standards are structurally identical to the native glycans but can be differentiated based on mass. These internal standards follow the native glycans throughout the sample preparation and measurement process allowing for correction of losses incurred during purification, incomplete derivatization, and ion suppression/ion enhancement. The determined concentrations from absolute quantitation can be compared between platforms and are necessary for determining clinical cut-offs, tracking pharmacokinetics, and including in regulatory filings. Absolute quantitation requires significant resources to generate or purchase a library of labeled glycans but is necessary when the concentration of the glycan is the desired clinical readout.
Pseudo-absolute approaches bridge the methodological gap between relative and absolute quantification by employing chemically similar non-isotopic standards to generate response factor corrections that approximate molar abundances. These strategies utilize equimolar standard mixtures to establish class-specific correction factors accounting for differential ionization efficiencies between neutral and acidic glycans, thereby improving upon simple percentage data without requiring exhaustive isotope labeling. Normalization methodologies further enhance quantitative accuracy by incorporating single-point internal standards—often non-native oligosaccharides—to correct for procedural variations during sample preparation. Such approaches offer financially accessible alternatives for research applications demanding greater accuracy than relative methods provide, though they retain susceptibility to structural biases that absolute quantification eliminates.
The choice of which quantitation strategy should be used is highly dependent on the research question and resources available. When interrogating biological samples for changes in glycosylation profiles or comparing glycosylation phenotypes between cell lines, relative quantification is often sufficient. This can be the case when comparing many samples at once or when the fold change is more important than the exact quantity. In situations where quantitation is required for biomarker validation, clinical diagnostics, or biotherapeutic pharmacodynamics, absolute quantification is necessary. Examples of this include cases where a certain molar percentage is clinically relevant or required for release specifications. Pseudo-absolute quantitation falls between the two and can be useful during process development, preclinical studies, and sample tracking. While fully isotopic labeling of all samples may be cost-prohibitive, pseudo-quantitation can allow for comparison of semi-quantitative data.
Relative quantitative glycan analysis determines glycan levels based on how much of the total glycans present each glycan represents. These glycan percentages are reported rather than actual molarity amounts. Each glycan's signal is normalized to the sum of signals of all glycans present. This allows for normalization to unequal sample loading, detector sensitivity variations, and differences in derivatization between runs.
The basic assumption behind relative abundance measurements is that individual glycan peaks can be compared to each other once they have been normalized to the total glycan response of a sample. Upon separation by chromatography and detection using either fluorescence or mass spectrometry, the area of each peak is divided by the total glycan area to report each glycan's contribution as a percentage of the whole. This process assumes that each glycan yields a similar response during detection, which is something to keep in mind when comparing glycan classes that have significantly different chemistry, such as neutral glycans vs. sialylated or fucosylated glycans.
Relative quantification is widely used in throughput methods where relative changes in glycosylation are more important than knowing the exact molar ratio. Typical applications are biomarker studies where many samples need to be compared (e.g., profiling of cell lines or quality control during bioprocess development), where it is often enough to know that there is a shift in the amount of two glycoforms. Absolute quantification requires the use of stable isotope labeled standards and calibration curves which is costly. Relative quantification on the other hand only requires an assay with good precision.
The relative simplicity of analysis using relative quantification can mask issues that must be considered when evaluating the data generated. Relative quantification does not allow for the identification of overall glycan upregulation or downregulation. If all glycans change by the same amount during a process or treatment condition, relative quantification will report the percentage of each glycan species to be the same as if there were no changes at all. Additionally, differing glycans can have differing response to detection due to structure (neutral vs. sialic acid-containing glycans) as well as matrix, incomplete derivatization, and co-eluting compounds. Ionization efficiency and fluorescence responses will affect the ability to compare glycan levels in one sample versus another using relative quantification techniques.
Relative quantitation has also been applied in several scenarios, such as profiling glycosylation between diseased tissue and controls as biomarkers for disease. Relative quantitation can be used to quickly assess lot-to-lot variations or biosimilar comparisons, where one simply needs to know if the glycoform distribution falls within some predefined acceptance range. Relative glycoprofiling has also been applied in cell culture process development as changes in glycosylation can be monitored as process parameters are changed. This can be done in line with Quality by Design principles, without the need for developing an absolute quantitation method.
Absolute quantitative glycan analysis provides absolute molar amounts for each glycan species after calibration curves have been constructed with chemical synthesized standards. Absolute quantitation methods are different from relative quantitation methods because they allow for the comparison between platforms and over time independent of concentration. Accounting for loss during preparation, matrix effects, and instrument response with the use of internal standards generates traceable quantitative values which can be used for clinical reporting as well as for regulatory submissions.
Absolute quantification is usually based on calibrating to known quantities of standards with defined structure. Standards are used to create a standard curve and are often prepared as a series of dilutions weighed out on a scale. Ideally, an isotopically labeled version of the analyte would be used as the internal standard since they co-elute but can be differentiated by mass spectrometry. Glycans labeled with heavy isotopes like carbon-13 or deuterium can act as internal standards to account for losses during enzymatic release, derivitization, and during LC injection/elution. Quantification will then be accurate for the amount present in the sample and not the amount that made it through the process.
Absolute quantitation may be carried out using external standard calibration curves in a solvent-based matrix or by using an internal standard containing an isotopically labeled reference compound (preferably the former). Calibration curves normalize variation between runs. Use of an internal standard corrects for differences between the analyte of interest and the internal standard so it is assumed that the analyte of interest and internal standard will behave identically during the analytical procedure. The matrix for the external standard calibration curve should match that of the sample as closely as possible to correct for ion suppression during chromatography. Response factors may vary for different classes of glycans (neutral vs. acidic), so care must be taken to generate statistically valid quantitative comparisons for each structural class of interest.
General pipeline of gQuant for MS-based glycan quantitation using stable isotope labeling.2,5
Limitations of absolute quantification include the limited commercial availability of various high purity glycan standards, especially for uncommon or complex structures such as highly branched glycans. Isotopically labeled internal standards must be synthesized or purchased, which can take significant time and effort, and therefore absolute quantification has often only been done after full method development for a limited number of high-interest targets, rather than for entire glycomes. Additionally, it is often assumed that ionization efficiency is the same among glycans of different structure, which is not always true. For example, glycan ionization detected by MS can vary greatly with changes in sialic acid and fucose content on glycans. All of these considerations require significant method development, which is not practical for many laboratories wishing to perform absolute quantification.
One example where absolute quantification becomes necessary is during the development and manufacturing of biopharmaceuticals. Often glycan levels on biopharmaceuticals are Quality Attributes that have large effects on safety and efficacy of the drug. Regulators require quantifiable data that is traceable to a reference standard in order to ensure batch-to-batch consistency during production as well as establish clinically significant specifications for glycosylation. Absolute quantification allows for direct tracking of glycans that may change during manufacturing processes, enables comparability studies for biosimilars that require identical concentration values and establishes definitive concentration values needed for regulatory submissions.
Methods of pseudo-absolute quantification (semi-quantitative methods) fill the void between relative quantification methods and absolute quantification methods by using internal standards that are not isotopically-labeled and/or response factor normalization to estimate absolute molar quantities without large libraries of stable isotope-labeled compounds. Many different chemically synthesized standards can be used to control for variation among samples and improve confidence in quantification without being cost prohibitive for typical laboratory use.
Absolute approaches use unlabeled glycans as internal standards to track sample loss during processing and correct for ionization efficiency during MS detection. Response factors are calculated using a mixture of standards at equal molar ratios to correct for differences in MS response between neutral and acidic glycans. Percentages can be adjusted using these factors on unknown samples for improved quantitation over just percent distributions. This method is limited by assuming that the structures of standards and samples are similar, which may not be true for all glycans.
Batch normalization in pseudo-absolute quantitation is dependent on including reference standards between runs. Adding the same amount of internal standards into each sample allows you to normalize the peak area from one run to another. This technique allows you to compare two separate sample batches. This is extremely useful when you need to compare absolute concentrations from experiments that took place over long periods of time or different labs.
Higher confidence in quantitative measures can be obtained in the lack of appropriate isotopically labeled standards by utilizing selective mass spectrometry approaches and chemical derivatization techniques to normalize ionization responses. Approaches such as multiplexed isobaric labeling allow comparison of samples within the same analytical batch removing between-run variation. The selectivity of multiple reaction monitoring and pseudo-fragmentation reactions increase signal to noise attributes and allow semi-quantitative comparisons that near absolute quantities for selected glycans.
Quantification of glycans requires extraction and preparation of the analytes prior to measurement. Extraction or release, purification, and labeling steps are sources of error that may introduce variability into glycan analysis. Quantitative confidence in glycan analysis begins with sample preparation. Variations in extraction or release methods, losses during purification, instability of glycans during purification and labeling, incomplete labeling efficiency all contribute to overall quantitative accuracy. Glycan preparation can introduce variability that can be greater than that seen between biological samples. Quantitative glycan analytics requires standardization to minimize error and produce replicable results that can be used for comparative purposes or to meet regulatory requirements.
Table 2 Systematic Error Sources in Glycan Sample Preparation
| Preparation Stage | Error Mechanism | Impact on Quantitative Fidelity | Corrective Approach |
| Enzymatic release | Incomplete deglycosylation; variable accessibility | Underestimation of glycan abundance; skewed compositional profiles | Optimized incubation protocols; surfactant-assisted unfolding |
| Sample purification | Non-specific adsorption; differential recovery | Irreproducible recovery between replicates; loss of minor species | Carrier additions; optimized binding conditions |
| Chemical labeling | Incomplete derivatization; structural heterogeneity | Biased ionization response; artifact generation | Reaction condition standardization; excess reagent deployment |
| Batch processing | Temporal drift; environmental variability | Inconsistent quantification across cohorts; false biological signals | Process automation; randomized processing sequences |
Partial release of glycans from glycoproteins is another factor limiting quantitative determinations since many glycosylation sites are sterically inaccessible to releasing enzymes. Additionally, chemical degradation of sensitive modifications also takes place during the often rigorous release conditions. Loss of sample during purification also occurs due to nonspecific binding to hydrophobic surfaces. Sample loss can also occur due to oxidative loss of sialic acid residues and trimming reactions at reducing ends. These factors make accurate quantitation difficult, especially for low abundance glycans since differences in loss between abundant and trace glycans can skew their perceived ratios.
Derivatization chemistry can lead to bias in quantitation if it does not proceed to completion for all glycans. Reaction efficiencies may vary between glycans of different structure. This may be because certain glycans are more difficult to label due to limited accessibility of reactive groups, or steric hindrance. Labeling efficiencies are often lower for sialylated glycans than neutral glycans due to charge repulsion or self interactions. Permethylating acidic sugars will increase stability of certain modifications that may otherwise be labile. Permethylating these groups may also lead to incomplete methylation esterification of hydroxyl groups. If reagent does not modify all glycans in a sample incomplete reactions lead to unlabeled glycans that will not be detected. Too much reagent can create additional byproducts that can complicate separation and cause ion suppression or other mass spectral interference.
For High-throughput studies, batch effects should be carefully controlled as slight differences in reagent efficacy over time, ambient humidity changes, and pipetting precision add up and result in large magnitude variations that obscure true biological differences. Batch effects introduce artificial differences between independently run groups that can be falsely attributed to disease-state changes. The use of standards at the beginning and end of assays, robotic platforms that minimize human pipetting errors, and randomizing experimental groups between batches help to control for these unwanted changes so that measured differences are reflective of true glycomic alterations.
Achieving chromatography-mass spectrometry compatible separations requires careful optimization of the chromatographic separation efficiency, the consistency of ionization, and the stability of the analytical system to allow for biologically robust quantitation of glycans. The chromatography coupled approach introduces additional sources of error including co-eluting isomers, variation in response between glycan classes in mass spectrometry, and time-dependent changes in the analytical system. These can be overcome through selection of chromatographic columns that separate isomers, additives to the mobile phase that equalize electrospray ionization between neutral and acidic glycans, and quality control samples run during the analysis.
The chromatographic resolution of glycan isomers on a stationary phase is essential for quantitation because undistinguishable masses arriving at the detector simultaneously cannot be integrated to yield meaningful peak areas. If they are not chromatographically resolved, measuring relative peak areas becomes meaningless and can lead to biased estimations of abundance. Chromatographic integration may not accurately resolve partially overlapping peaks, especially if one peak (minor glycoform) rides on the shoulder of another peak (major glycoform), leading to biased overestimation of the minor peak. Columns that can resolve glycans such as porous graphitized carbon columns or amide functionalized hydrophilic interaction liquid chromatography (HILIC) columns can separate structural isomers of glycans. There is typically a trade-off between sufficient resolution to confidently integrate each peak and running speed.
Ionization of neutral oligosaccharides is less efficient than acidic glycans with terminal sialic acids or sulfate groups in electrospray mass spectrometry, due to their different ionization properties. Signal suppression by co-eluting glycans or matrix material can also limit linearity of detection and dynamic range, typically impacting analytes present at lower concentrations. Addition of substances to the mobile phase (e.g., amino acids, volatile ion-pair reagents) can improve ionization efficiency uniformly for all glycans and derivatization with hydrophobic labels through reductive amination improves detection sensitivity and reduces response differences between classes.
Another major issue is the time course changes in MS response and chromatography (known as temporal drift). Samples analyzed earlier in the run may respond differently than those analyzed later due to changes in ambient conditions, column bleeding, or source/channel contamination. Including a reference standard at the beginning and end of your samples will help you track this problem. Shuffling the order of your samples will spread this systematic error across all of your samples. Additionally you can correct for this by normalizing to an internal standard that co-elutes with your glycan of interest.
Normalization, quality control and data reproducibility are aspects of glycan profiling which include statistical approaches for adjusting between-run systematic errors, controlling measurement accuracy, and standardized protocols for making results easily reproducible in other laboratories. These efforts help to differentiate biological variation from technical noise. Examples include scaling factor normalization of instrument drift or sample preparation variations, and assessing assay performance with controls. If normalization is not taken into consideration, glycomic data may show differences that are not attributed to biological alterations in glycosylation but rather differences in technical variability and may limit biomarker discovery or comparison of data collected from multiple studies.
Technical replicates measure technical variability versus biological variation by analyzing multiple aliquots from the same sample preparation under the same conditions. Several quality control metrics numerically capture reproducibility based on statistical calculations of precision at various scales, allowing users to identify aberrant values and validate the precision of their workflow. These criteria can be used to ensure that changes in glycan levels are significant compared to technical variation, while also establishing confidence in the robustness of your analysis for applications like high-throughput discovery.
System suitability tests are samples used to confirm that a chromatographic separation, mass spectrometer sensitivity, and retention time are adequate before beginning a run of samples. These samples can be used to confirm the system meets acceptance criteria during lengthy runs so that system parameters are stable. If the system changes during the run, poor data may be produced. System suitability ensures poor data is not produced by catching system failures before samples are affected.
The main challenges to achieving comparable results across laboratories include differences in chemistry used to prepare samples for analysis, differences in chromatography selectivity, differences in ionization efficiency from instrument to instrument, differences in software used to process the raw data and determine glycan quantities, and differences in reporting outputs. For example, two laboratories running the same sample may report completely different glycan quantities due to differences in signal background subtractions and normalization procedures. Alignment of standards as well as output reporting will help reduce variability and allow for data collected from multiple sources to be comparable for translation into clinical practice.
The interpretation of glycans when measured quantitatively in biopharmaceutical and biological samples can be challenging. Structural differences observed between glycan molecules must be identified as being either biologically significant changes or technical changes that have no significance in vivo. Rigorous statistical analysis that takes into account analytical variability as well as biologic variability is necessary to define whether differences are significant, and if so, what the relationship is between the measured structure and the activity of the glycoprotein (efficacy, immunogenicity, PK, etc.). Manufacturing process control as well as setting specification limits rely heavily on the accurate interpretation of glycans in a biological context.
Significant changes refer to differences in glycosylation that are larger than established thresholds for changes that are believed to have biological or clinical effect, including therapeutic activity. These differences should be distinguishable from the background variability due to analytical variability and natural glycosylation variability. The thresholds would need to be established using structure activity relationship studies to determine which glycans changes would be expected to change properties of interest such as target engagement or half-life. Guidelines recommend that any change that falls outside of established acceptance criteria must be evaluated for impact on safety and/or efficacy so that shifts in glycosylation will not result in product batches being accepted or rejected on specifications that are not biologically justified.
Variations due to biological processes are defined as originating from intrinsic biological processes including metabolism, protein turnover and disease states. Technical noise includes sample preparation and physical processing artifacts including batch effects and instrument noise. Separating these sources of variation is crucial when analyzing biological data, as biological variation can be informative (i.e. disease state) or a result of cell stress, while technical noise will only add uncertainty to glycosylation measurement. However, with proper biological replication and experimental design quality control, one can determine the portion of variation due to technical effects vs. biological variation so that significant changes are likely due to biological effects.
Variations in glycan levels can affect critical quality attributes of biopharmaceuticals including efficacy, clearance, and immunogenicity. For example, changes in individual glycoforms can increase or decrease ADCC activity, affect complement fixation, or alter FcRn-mediated recycling, impacting dose-frequency and clearance. Characterization of glycosylation as a quality attribute is required by regulatory agencies and the associated quantitative criteria are used to ensure comparability between manufacturing batches such that any structural differences fall within a range that have been shown to have the same activity.
When choosing a quantitative approach for glycan analysis, important factors to consider include sample complexity, throughput demands and quantitative needs. Sample complexity and quantitative needs will vary based on whether the study is hypothesis generating or if it is intended for regulatory submission. Relative quantification can be useful for hypothesis generating studies where high throughput and a general understanding of glycan levels is necessary. Absolute quantification will likely be necessary for more stringent studies and regulatory submissions. Regardless of which quantitative approach is chosen, it is important to consider how the data generated will meet the desired confidence level needed for the biological question being studied.
In research settings, discovery-based workflows are accepted where only relative quantitation is necessary for finding changes in glycosylation under different disease conditions or treatment settings. Thus research applications generally allow for higher technical variability and experimental biases if the methodology yields maximal glycan coverage and structural resolution. For biopharmaceutical applications, absolute quantitation with CRM's are needed for determining key product quality attributes, controlling batch-to-batch variability, and meeting regulatory demands for data reproducibility and traceability. This primarily drives whether you need the highest level of structural information versus having well-established, validated quantitative units for control purposes.
A choice of method often represents a compromise between desire for quantitative rigor versus need for high-throughput and/or low cost. Relative quantification allows for high-throughput (potentially hundreds of samples) and low cost, but provides insufficient precision to be clinically actionable. Absolute quantification against a stable isotope-labeled internal standard provides the "absolute" molarity needed for certain applications such as regulatory submissions, but is more costly (requires purchase of the stable isotope-labeled compound) and time-consuming. Pseudo-absolute methods provide a middle-ground between relative and fully isotope-labeled methods.
It is critical to match the glycan profiling approach to the goal of the study. Discovery-type experiments where one intends to identify potential glycan biomarkers across many samples will likely take advantage of high-throughput relative methods to quickly identify relative shifts in glycans. Absolute quantification is necessary when determining a minimum therapeutic concentration, such as in pharmacokinetics experiments or during biosimilar interoperability studies to determine if two drugs will have the same clinical effect. Pseudo-absolute approaches may be used to track manufacturing drift during process development studies as they are less expensive while still providing adequate quantitation. The method chosen should provide data that will allow one to make decisions that have reasonable risk if the glycans change.
Quantitative glycan analysis faces significant technical challenges that intrinsically limit the accuracy and reproducibility between instruments. This often limits reported precision of glycan quantitation and must be considered when evaluating perceived accuracy. The technical challenges of quantifying glycans are due to their structural complexity and lack of appropriate standards as well as error propagation through multistep processing steps.
Table 3 Systematic Limitations in Quantitative Glycan Profiling
| Limitation Category | Fundamental Challenge | Impact on Quantitative Fidelity | Mitigation Approaches |
| Standard availability | Structural diversity exceeds commercial standard coverage | Inaccurate calibration across glycan classes | In-house standard development; isotopic labeling |
| Error propagation | Multi-step workflow complexity | Accumulated uncertainty obscuring biological variation | Process automation; internal standardization |
| Precision perception | Instrumental sensitivity masking biological heterogeneity | False confidence in quantitative stability | Replication strategies; uncertainty quantification |
One issue impeding absolute quantification is the lack of certified reference materials that span the vast structural diversity of glycans found in nature. Standards that are commercially accessible generally span only the most prevalent and studied glycan structures. Rare glycans and post-translationally modified glycans do not necessarily have standards that closely match their structures. Consequently analysts must either choose standards that are structurally different to serve as a proxy or quantify relatively. Using structurally different standards makes it impossible to know the absolute number of moles present. Isotopically labeled versions of glycans are also limited which prevents analysts from using adequate internal standards to correct for losses and inconsistent ionization of glycans.
Characterization of glycans typically involves a series of analytical steps, consisting of release (enzymatic or chemical), derivatization (chemical modification), separation (LC and/or CE), and detection (mass spectrometry). The uncertainty associated with each of these steps accumulates to result in uncertainty of the final measurement. Steps such as incomplete release of glycans from obstructed sites on proteins, incomplete derivatization (due to steric hindrance), incomplete recovery/purification, and poor ionization efficiency lead to measurement bias. Each analytical step has an associated error that accumulates to exceed biological variability between samples, potentially leading to false discovery of biologically significant alterations in glycosylation.
The use of high-resolution mass spectrometry systems currently generates high-quality data with significant signal-to-noise ratios, leading researchers to sometimes place false confidence in the calculated abundances of glycans being reported. Instrumental accuracy does not always account for errors due to matrix suppression, poor chromatographic resolution of isomers, or response differences between neutral and acidic glycans. Misinterpretation of data can occur when percent alterations in glycan composition are considered without looking at overall glycan quantities, or when insignificant changes are deemed significant biologically when they fall within an analytical range of error.
Use of Quantitative glycan analysis can be thought of as a decision support tool during development of biopharmaceuticals. Decisions must be made at every stage of development from initial clone screening to process optimization and eventual regulatory filing. Each decision needs to be balanced with the available resources and overall needs of the project. Quantitative glycan analyses can identify unfavorable glycoforms early on in cell line development and can help determine if process changes will improve product efficacy. However, choices must be made during discovery analysis to allow for high throughput using relative quantitative methods and during regulatory filings absolute quantification may be required using certified reference materials.
Quantitative glycan profiling is essential for understanding glycosylation changes in research, biopharmaceutical development, and quality control environments. However, not all quantitative approaches offer the same level of accuracy, reproducibility, or regulatory suitability. Selecting the appropriate strategy—relative, absolute, or pseudo-absolute quantification—depends on study objectives, available standards, and required analytical rigor. Our quantitative glycan profiling services are designed to deliver reliable, well-documented data that supports scientific decision-making and regulatory compliance.
We provide tailored quantitative glycomics workflows aligned with project requirements:
Relative Quantification: Widely used in research and early development, relative quantification measures the proportion of each glycan species within a sample. Using optimized HILIC-LC with fluorescent labeling or LC–MS detection, we ensure robust peak integration, reproducibility, and cross-sample comparability.
Absolute Quantification: For applications requiring defined concentration values, we implement absolute quantification strategies using authentic glycan standards, calibration curves, and validated response factors. This approach is particularly relevant in regulated biopharmaceutical environments where glycosylation is classified as a critical quality attribute (CQA).
Pseudo-Absolute Quantification: When authentic standards are limited, pseudo-absolute approaches use internal standards and normalization strategies to enhance quantitative accuracy. This method balances practicality with improved confidence, especially in complex or large-scale studies.
Across all workflows, we carefully control:
This integrated control minimizes cumulative analytical bias and supports reliable quantification.
Accurate quantification requires more than sensitive instrumentation—it requires rigorous quality control and transparent documentation. Our quantitative glycan profiling services include:
For biopharmaceutical applications, we support trending analysis, comparability studies, and documentation suitable for regulatory submission. All reports clearly describe methodology, quantification strategy, validation status, and potential limitations, ensuring defensible and transparent data interpretation.
If you require reliable relative, absolute, or pseudo-absolute glycan quantification for research, process development, or quality control, our team provides customized, quality-controlled analytical solutions. Contact us to discuss your quantitative requirements, regulatory considerations, and timeline for comprehensive glycan analysis and reporting.
References
